Trevi Therapeutics, Inc. (TRVI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Trevi Therapeutics, Inc. (TRVI) closed at USD 12.06 on 2026-10-14, a change of +14.5 % over the past year, with a market capitalization of USD 1.73B.

Trevi Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Trevi Therapeutics, Inc. key figures

Previous close

USD 12.06 (2026-10-14)

1-year change

+14.5 %

Market cap

USD 1.73B

Enterprise value

USD 1.41B

P/E ratio (trailing)

-35.62

P/E ratio (forward)

-20.99

EPS (trailing)

-0.34

EPS (forward)

-0.58

PEG ratio

n/a

Price to book

5.37

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.10

Employees

34

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Trevi Therapeutics, Inc. and compare it with other stocks.